NCT05438602: A reported trial by Pfizer
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05438602 |
|---|---|
| Title | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 3, 2022 |
| Completion date | July 17, 2023 |
| Required reporting date | July 16, 2024, midnight |
| Actual reporting date | July 15, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |